Literature DB >> 20489042

Insulin sensitivity and body composition in cirrhosis: changes after TIPS.

Peter Holland-Fischer1, Michael Festersen Nielsen, Hendrik Vilstrup, Dennis Tønner-Nielsen, Anette Mengel, Ole Schmitz, Henning Grønbaek.   

Abstract

Insertion of a transjugular intrahepatic porto-systemic shunt (TIPS) increases body cell mass (BCM) in patients with liver cirrhosis. The responsible mechanism is unidentified, but may involve changes in insulin sensitivity and glucose metabolism. Eleven patients with liver cirrhosis were examined before and 6 mo after a TIPS procedure with bioimpedance analyses, 2-h oral glucose tolerance tests, and two-step hyperinsulinemic euglycemic clamp with tracer-determined endogenous glucose production. After TIPS, BCM increased by 4.8 kg [confidence interval (CI): 2.7-7.3]. Fasting (f)-insulin increased from 123 +/- 81 to 193 +/- 124 pmol/l (P = 0.03), whereas f-glucose was unchanged (6.0 +/- 0.8 vs. 6.2 +/- 1.0 mmol/l). Glucose and insulin oral glucose tolerance test area under the curve increased by 14% (CI: 7-22%) and 53% (CI: 14-90%), respectively, P < 0.05. The C-peptide-to-insulin ratio decreased by 21% (CI: 8-35%, P = 0.01). Insulin sensitivity based on glucose infusion rate (4.69 +/- 1.82 vs. 4.85 +/- 2.37 mg.kg(-1).min(-1)) and glucose tracer-based rate of disappearance were unchanged (5.01 +/- 1.61 vs. 4.97 +/- 2.13 mg.kg(-1).min(-1)). Despite a further increase in peripheral hyperinsulinemia, f-endogenous glucose production did not change between study days (2.01 +/- 0.42 vs. 2.42 +/- 0.58 mg.kg(-1).min(-1)) and was suppressed equally by insulin (1.1 +/- 0.1 vs. 1.0 +/- 0.1 mg.kg(-1).min(-1)). Insulin clearance, growth hormone, cortisol, and glucagon levels were unchanged. BCM improvement did not correlate with the measured variables. After TIPS, BCM rose, despite enhanced hyperinsulinemia and aggravated glucose intolerance, but unchanged peripheral and hepatic insulin sensitivity. This apparent discrepancy may be ascribed to shunt-related decreased insulin exposure to the liver cells. However, the anabolic effect of TIPS seems not to be related to improvements in insulin sensitivity and remains mechanistically unexplained.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20489042     DOI: 10.1152/ajpgi.00375.2009

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  4 in total

1.  Circulating fibroblast growth factor 21 in patients with liver cirrhosis.

Authors:  Sabrina Krautbauer; Lisa Rein-Fischboeck; Elisabeth M Haberl; Rebekka Pohl; Reiner Wiest; Christa Buechler
Journal:  Clin Exp Med       Date:  2017-07-25       Impact factor: 3.984

2.  Occlusion of portosystemic shunts improves hyperinsulinemia due to insulin resistance in cirrhotic patients with portal hypertension.

Authors:  Tsuyoshi Ishikawa; Shogo Shiratsuki; Takashi Matsuda; Takuya Iwamoto; Taro Takami; Koichi Uchida; Shuji Terai; Takahiro Yamasaki; Isao Sakaida
Journal:  J Gastroenterol       Date:  2013-10-05       Impact factor: 7.527

Review 3.  Adipokines in Liver Cirrhosis.

Authors:  Christa Buechler; Elisabeth M Haberl; Lisa Rein-Fischboeck; Charalampos Aslanidis
Journal:  Int J Mol Sci       Date:  2017-06-29       Impact factor: 5.923

4.  Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study.

Authors:  Shunsuke Shiba; Po-Sung Chu; Nobuhiro Nakamoto; Karin Yamataka; Nobuhito Taniki; Keisuke Ojiro; Akihiro Yamaguchi; Rei Morikawa; Aya Yoshida; Akihiko Ikura; Hirotoshi Ebinuma; Hidetsugu Saito; Takanori Kanai
Journal:  BMC Gastroenterol       Date:  2020-03-05       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.